Premium
P4‐002: A Phase 3, 26‐Week, Double‐Blind, Randomized, Placebo‐Controlled Study of AC‐1204 in Mild‐to‐Moderate Alzheimer's Disease: Study Design and Progress
Author(s) -
Farlow Martin R.,
Gold Michael,
Henderson Samuel,
Greer Sabrina,
Vogel Janet,
Shenkin Aaron
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.2091
Subject(s) - placebo , ketosis , medicine , randomized controlled trial , dementia , clinical endpoint , disease , pediatrics , endocrinology , diabetes mellitus , pathology , alternative medicine
P4-001 A LARGE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING RVT-101, A NEUROTRANSMITTER-TARGETED THERAPY, IN SUBJECTS WITH MILD-TOMODERATE ALZHEIMER’S DISEASE ON DONEPEZILTREATMENT: PHASE 3 MINDSET STUDY DESIGN Ilise Lombardo, Shari Coslett, David W. Liu, Kunal S. Kishnani, Benjamin Zimmer, Lawrence Friedhoff, Axovant Sciences, Inc., New York, NY, USA; 2 Roivant Sciences, Inc., New York, NY, USA. Contact e-mail: ilise.lombardo@axovant.com